World Journal of Pharmaceutical Science and Research
www.wjpsronline.com
Review Article
ISSN: 2583-6579
SJIF Impact Factor: 5.111
Year - 2025
Volume: 4; Issue: 3
Page: 1674-1688

REVOLUTIONIZING INSULIN SUPPLY: UNVEILING THE POWER OF rDNA TECHNOLOGY IN PRODUCTION

Anshul Sharma*[1], Shikha Virk[1] and Amrit Sarwara[2]

[1]Assistant Professor, Chandigarh College of Pharmacy CGC Landran, Mohali 140307.

[2]Research Scholar, Chandigarh College of Pharmacy CGC Landran, Mohali 140307.

Article Received: 04 May 2025 | | Article Revised: 25 June 2025 | | Article Accepted: 15 July 2025

***Corresponding Author: Anshul Sharma**
Assistant Professor, Chandigarh College of Pharmacy CGC Landran, Mohali 140307.
DOI: https://doi.org/10.5281/zenodo.16364000

How to cite this Article: Anshul Sharma, Shikha Virk, Amrit Sarwara (2025) REVOLUTIONIZING INSULIN SUPPLY: UNVEILING THE POWER OF RDNA TECHNOLOGY IN PRODUCTION. World Journal of Pharmaceutical Science and Research, 4(3), 1674-1688. https://doi.org/10.5281/zenodo.16364000

ABSTRACT

Biotechnology, a technology-driven branch of biology, finds extensive applications in agriculture, pharmaceuticals, and human medicine. While pharmaceutical biotechnology traditionally relies on fermentation and bioprocessing, a paradigm shift in biotechnology and pharmaceutical research has modernized concepts and processes. The biotechnological revolution has transformed drug research, development, manufacturing, and marketing. Among the notable achievements is the production of human insulin using rDNA technology, a groundbreaking advancement in medical science. Human recombinant insulin, synthesized under in vitro conditions, has become a cornerstone in treating various diseases and is widely utilized in clinical research. Insulin replacement therapy, the standard for type 1 and advanced type 2 diabetes, has evolved from porcine and bovine sources to semisynthetic human insulin. The advent of recombinant DNA technology marked a significant leap, enabling biosynthetic production of human insulin in microorganisms like E.coli and yeast. This breakthrough ensured reliable, cost-effective, and large-scale global insulin supplies. The purity and pharmaceutical quality of recombinant human insulin surpassed its predecessors, allowing smooth transitions for patients from animal or semisynthetic insulin with no change in dose. This technology addresses the global demand for a consistent insulin supply. This unique role of recombinant DNA technology in formulating human insulin, highlighting its distinctive place in the biotechnological landscape, marking it as one of the pioneering products in the field. This offers a concise retrospective assessment of early clinical studies with recombinant insulins, highlighting their pivotal role in enhancing insulin therapy worldwide. Clinical vigilance post-transition is emphasized to confirm ongoing efficacy.

KEYWORD: Diabetes mellitus, Insulin, recombinant DNA (rDNA), Fermentation.

INTRODUCTION

Preparations of insulin made from bovine or porcine pancreatic tissue have been the mainstay of diabetes therapy since 1923, when commercial manufacturing of insulin was introduced in Europe and the US.[1].As the global clinical need for insulin grew, the usage of insulin derived from animals began to pose a challenge. After the molecular structure of human insulin was discovered, attempts were made to synthesise the protein entirely chemically, but the results did not yield a supply that was useful for therapeutic purposes.[2,3] The next steps in creating clinically suitable human insulin from animal insulin were purification and amino acid exchange.[4-6] Semisynthetic human insulin was the modified material used to make all pharmaceutical formulations, including premixed insulins and normal and neutral protamine Hagedorn [NPH]." The need for "human insulin" in therapeutic settings and the change in insulin source sparked a contentious discussion when semisynthetic human insulin was first made available for purchase. The main points of discussion were the benefits of further purification, including reducing the likelihood of local and systemic allergic responses and reducing the amount of insulin-directed antibodies produced during treatment. "Recombinant human insulin" becomes widely available through the use of fermentation in microorganisms and recombinant DNA technologies (bacteria or yeast). Recombinant insulin is more pure and consistently of higher quality than semisynthetic insulin. Eli Lilly quickly applied the Genentech-developed biosynthesis method to the commercial setting.[7,8] Following it, clinical and pharmacological protocols were created by Novo Nordisk and Sanofi (formerly Hoechst AG/Hoechst Marion Roussel/Aventis). The aforementioned businesses are at the forefront of human insulin recombinant manufacture thanks to their comprehensive evaluations and summaries of its therapeutic qualities.[9] Despite the discovery of insulin analogues, human insulin recombinant has remained the standard of care since it was first used in clinical therapy in 1982.[10] The worldwide treatment recommendations.[11–12] address the standard of care for diabetic therapies. A number of clinical trials involving human recombinant insulins that were filed for regulatory clearance have not been made completely public. A full account of bioequivalency experiments employing recombinant Insuman(r) (Sanofi, Paris, France) may be found in recent papers.

rDNA TECHNOLOGY

Genetic engineering, sometimes referred to as the use of recombinant DNA (rDNA) technology, is the process of manipulating DNA molecules to produce novel sequences that do not exist naturally. Several industries, including manufacturing, agriculture, and medicine, have changed as a result of this technology.[13]

Explanation of rDNA Technology and how it Works

Isolation of Target DNA: The first step in the procedure is to isolate the desired protein-encoding gene from the relevant DNA sequence. This would include locating and isolating the human insulin gene in the instance of insulin synthesis.

Cutting DNA with Restriction Enzymes: Next, the DNA is sliced at precise spots using specialised enzymes known as restriction enzymes. These enzymes cleave the DNA at or close to recognition sites, which are particular DNA sequences that they can identify. As a result, complementary DNA fragments with sticky ends are produced.[14]

Insertion of Target DNA into a Vector: An organism's host DNA is transferred into the target DNA using a vector, which is typically a plasmid or viral genome. Suitable sticky ends are produced by splitting open the vector with the same restriction enzymes that are used to cut the target DNA. A recombinant DNA molecule is created by using DNA ligase to join the DNA strands after the target DNA fragment containing the insulin gene has been put into the vector.[15]

Introduction into Host Organism: The human insulin gene is now present in the recombinant DNA molecule, which is inserted into a host organism like yeast or bacteria. Numerous techniques, such as transfection for eukaryotic cells or transformation for bacteria, can be used to accomplish this. Depending on the type of vector employed, once within the host, the recombinant DNA either replicates autonomously or integrates into the host genome.[15]

Expression of the Insulin Gene: The cellular machinery of the host organism reads the inserted insulin gene and makes insulin protein in accordance with the instructions encoded in it. The host cell then synthesises, folds, and processes the insulin protein.

Harvesting and Purification: Once there is enough insulin produced, the host cells are taken out and the insulin protein is separated from the various parts of the cell. The insulin protein is isolated and impurities are eliminated using a variety of purification methods, including chromatography, to produce extremely pure insulin that is appropriate for therapeutic usage.[16]



Fig. 1: Steps Involved in rDNA Technology.

HISTORY

The initial discovery of insulin in 1922 marked a significant advancement in the diagnosis and treatment of diabetes. Even before insulin was identified, it was hypothesised that the pancreas secreted a substance that controlled the metabolism of carbohydrates.[17] For years, attempts to synthesise pancreatic extracts to reduce blood glucose were unsuccessful due to toxicity and pollutants.[18] Frederick Banting, an orthopaedic physician, developed the technique for isolating pancreatic islet extracts. Pancreatic ducts were clamped until the acini began to fail, at which time the islets were removed to keep the dogs alive. He requested lab space from John Macleod, a physiology professor and department head at the University of Toronto. Macleod provided Charles Best, an undergraduate research assistant to lab space, ten canines for his studies, and other tools. The tests began on May 17, 1921, and by September, it had been determined that the depancreatized dog had diabetes and that their pancreas extract, which they called isletin, could be injected intravenously to lower blood sugar. Biochemist J.B. Collip joined the group at the end of 1921 and helped get the isletin ready for consumption by people. On January 11, 1922, Banting and Best gave the pancreatic extract on a 14-year-old child for the first time; the child developed a sterile abscess, the extract had minimal effect on ketosis, and the extract modestly decreased blood glucose levels. Collip subsequently injected the purified extract, with positive

results, that same year. Ketonuria disappeared along with a decrease in blood glucose and glucosuria. Rosenfeld documented successful results in six additional instances.[18] For their findings, Batting and Malceid were granted the Nobel Prize. Eli Lilly was unable to meet demand as the strength of the insulin it began producing from bovine pancreatic varied by up to 25% each lot. With the development of the isoelectric precipitating technique, animal insulin became more efficacious and purer, with lot-to-lot variation reduced to 10%. Because his wife had diabetes, August Krogh, a researcher at the University of Copenhagen, met with Macleod and Banting in 1923 to talk about insulin. He was granted permission by the University of Toronto to bring insulin to Scandinavia. A nonprofit organisation called Nordisk Insulin Laboratory began producing insulin.[19] Because the insulin formulation needed to be injected several times a day, researchers tried to increase its duration of effect. In order to prolong the effects of insulin, Danish chemist H.C. Hagedorn added protamine to it in the 1930s. Zinc was added by Scott and Fisher in Toronto in order to extend the duration of insulin action. These findings led to the introduction of longer-acting animal insulins onto the market. The half-life of insulin protamine zinc is 24–36 hours. With a half-life of 24 hours, isophane neutral protamine Hagedorn can be used with regular insulin.[20]

The three types of lente insulin—semilente, lente, and ultralente—have varied pharmacokinetics and effects depending on the proportion of zinc present. In 1978, David Goeddel and his collaborators at Genentech combined and used the insulin A- and B-chains which had been expressed in Escherichia coli to produce the first human recombinant DNA-based insulin. After that, Lilly and Genentech decided to sell rDNA insulin together. 1982 saw the release of the first rDNA-produced insulins, Humulin® R (rapid) and N (NPH, intermediate-acting). As people with diabetes started to live longer, the prevalence of chronic diabetes issues increased.

For the first time, the Diabetes Control and Complications Trial.[21] clearly showed a linear correlation between the degree of glycemic control and complications. Physiologic insulins were studied to reduce the incidence of hypoglycemia, the main obstacle to strict glycemic control. Physiologic insulins mimic basal and prandial insulin secretion. By changing the amino acid location, insulin's pharmacokinetics were changed, leading to faster absorption, a sooner peak of action, and a shorter period of action.[22] Lispro was first authorised as a quick-acting insulin analogue in 1996 and was subsequently approved in 2000. In 2004 (aspart), and in 2001 (glulisine).[23] Currently marketed basal insulin analogues, glargine (authorised in 2000; 13) and detemir (approved in 2005; 14) are the only two. When compared to asparagine, glycine is present at position A21, whereas arginine contains two more molecules at location B30 and a pH of 4.0. It causes a prolonged absorption with little peak activity at the point of injection site where it microprecipitates.[24, 25] An attached 14-carbon fatty acid chain to lysine at location B29 slows the absorption of insulin detemir.In lieu of conventional insulin administration techniques, Sanofi-Aventis and Pfizer developed exubera, the first inhalation insulin, which Pfizer then sold. It was laborious to use the inhaler apparatus. There was no increase in the physiological benefit when compared to insulin analogues with rapid-short acting.[26] It was taken off the market after two years because doctors and patients did not accept it.[27, 28]

STRUCTURE AND FUNCTION

The structure and function of Human insulin is represented in Fig – 2.



Fig. 2: Structure and Function of Human Insulin.

PRODUCTION OF HUMAN INSULIN

The initial phase in the process of making insulin that will be discussed here is the synthesis of proinsulin. There is also a second two-chain method that can be used to manufacture the insulin A and B chains separately. Recombinant E. coli is used to manufacture sufficient levels of proinsulin. To produce this recombinant protein, plasmids that synthesise proinsulin are introduced into E. coli.[29] cells. The altered cells are then cultured in tryptic soy broth supplemented with the antibiotic kanamycin monosulfate. The genome of the plasmid has a kanamycin monosulfate resistance gene in addition to the proinsulin coding genes, which permits the modified E. coli to survive in the broth.However, kanamycin monosulfate kills the untransformed E. coli cells.[30]. After the changed E. coli are obtained, the next step is to increase the cell count to initiate the synthesis of proinsulin inclusion bodies. To do this, the original transformed cells are injected and grown in a bioreactor under precisely controlled conditions to boost the production of insulin. Previously, the cells were grown in kanamycin monosulfate and tryptic broth. These factors consist of temperature (37°C), feed, foam, and pH . A tension level of 30% is maintained for the oxygen level by adjusting the quantity of glycerol-feeding.[31]

1) FERMENTATION AND PARAMETERS

In six 200ml test tubes, 0.5g of the initial converted E. Coli cells are cultured in 1 litre of tryptic soy broth solution supplemented with 0.5 gramme of kanamycin monosulfate. After growing in the medium for 24 hours at 37°C, the cells are put into a bioreactor to promote proliferation and proinsulin synthesis. After 24 hours, the transformed E. Coli has eaten and used up all of the nutrients that were in the test tubes and is placed in the bioreactor to continue growing. This bioreactor has an overall volume of 23L with an operational volume of 16L. Nine litres of new growth medium are combined with one litre of depleting media for development and E. coli in the bioreactor. From this point on, inorganic nutrients will be supplied to these cells in the form of carbon from yeast and glycerol, nitrogen from ammonium sulphate and thiamine, and both, as well as potassium dihydrogen phosphate and dipotassium phosphate, which also

function as pH buffers. Trace elements will be provided by sodium citrate, magnesium sulphate, and vitamin solution.[32].

2) CELL ISOLATION AND CENTRIFUGATION

Cell isolation is the first step in the release of the insulin generated by modified E. coli cells. This process is also called "cell harvesting" since the proinsulin inclusions are extracted using both centrifugation and filtration. The bacterial cells settle to the bottom during a 10-minute centrifugation at 7500 x g (8185 rpm) because E. coli has the greatest number of cells of any material in the growth medium. The thick combination that remains is then subjected to additional processing since it has a greater amount of cells from bacteria than the the supernatant which is disposed away.[33]

3) CELL LYSIS BY HOMOGENIZATION

Inside the cell's proinsulin inclusion bodies are proinsulin fusion proteins that serve as insulin precursor products. Because of their dense cluster nature, they are protected from the cytoplasm's conversion to the soluble form. In order to liberate these inclusion bodies, there are multiple methods for rupturing cell membranes. Using a blade-type homogenizer and high-pressure homogenization, this particular process also incorporates chemical alkali treatment [34] The mixture experiences compression, velocity, and a pressure decrease when it comes into interaction with the blade within the high-pressure homogenizer chamber. This is due to the tremendous turbulence and shear that is created. putting the medium and bacteria into the chamber quickly is how this is achieved.

4) INCLUSION BODY SEPARATION BY CENTRIFUGATION

After the E. coli have been lysed, it is required to separate the inclusion bodies from the cell debris. Reverse osmosis in this case can be achieved via centrifugation. Because the proinsulin inclusion bodies are dense, they will sink to the bottom. On the other hand, a higher centrifugation speed (15000 x g for 30 minutes) is required than before due to the inclusion bodies' lower density compared to the entire bacterial cells. After centrifugation, the supernatant is thrown away, leaving proinsulin and a few impurities in the tube.[35]

5) SOLUBILIZATION OF INCLUSION BODIES

After inclusion bodies separate, proinsulin is in a form that is insoluble and needs to be dissolved. To do this, denaturing chemicals such as urea and guanidium hydrochloric acid are applied, which causes the fusion proteins to be released. Following this process, proinsulin fusion proteins' disulfide connections are broken using reducing agents like DTT or β-mercaptoethanol. After solubilization, cleavage is performed as part of the traditional proinsulin process to create proinsulin. Alternatively, this could be done at a later phase of the process. Add 70% formic acid and cyanogen bromide to proinsulin in order to disrupt the peptide linker that connects it to its fusion protein partner.[36]

6) SULFITOLYSIS

Sulfitolysis starts with the introduction of reducing agents to break the disulfide bonds. These connections break during the solubilization procedure and other early purification steps. To encourage oxidation and maintain proinsulin in its unfolded state, sulfitolysis is performed in conjunction with a 6-hour solubilization interval and an addition of 0.8M Na2SO4 and 0.3M Na2SO4*H2O. Sulfite (SO3) ions are used to treat cysteine molecules in order to prevent the formation of incorrect disulfide bonds44. Each cysteine residue in the proinsulin molecule receives an addition of sulfite ions. However, the ZZ tail remains unaltered and is employed in further downstream processes since it does not include cysteine residues.[37]

7) ADDITIONAL SEPARATION

Centrifugation at 17700 x g for 33 minutes is needed to remove the contaminants and reagents from solubilization and sulfitolysis prior to renaturation.

8) DIALYSIS

This technique removes the dissolved substances and previously used denaturants without affecting the chemical outcome of the fusion protein. Buffers such as 10 mMTris-HCl (4 repetitions) must be added to get rid of substances like urea, DTT, and β-mercaptoethanol and to initiate the refolding process of the proinsulin fusion protein.[38]

9) RENATURATION

Renaturation, or the correct folding of proteins, depends on the correct formation of disulfide bonds. When β-mercaptoethanol and 1M glycine-sodium hydroxide buffer (pH 10.5 or above) are added to the fusion protein at an 18:1 molal ratio, the protein undergoes 20 hours of denaturation at 4°C. There are several strategies available. Two popular methods are as follows: (1) oxidising the reduced proinsulin with oxidative buffers such as glycine-sodium hydroxide or low molarity Tris-HCl; or (2) sulfothiolysis with sodium sulfite to convert the proinsulin to the S-hexa-sulfonated form, followed by the addition of redox reagents such as cysteamine, GSH, or cysteine couples.[39] Proper folding is one of the most crucial elements affecting the output of proinsulin products. Refolding is optimised when a high concentration of redox reagents is used, an accelerated oxidation rate is used, and the pH is kept at 9. Even in ideal circumstances, the yield is between 60% and 70%. Consequently, at this point in the production process, more research is required.[40]

10) VOLUME REDUCTION

It is necessary to remove the chemicals and buffers used during renaturation in order to isolate the proinsulin product. To achieve this, adjust the pH with a weak acid and centrifuge the mixture at 17700 x g for 33 minutes. One potential stand-in method is sedimentation.[50]

11) AFFINITY CHROMATOGRAPHY

Not the growth of altered bacteria, but downstream purification steps are believed to be responsible for more than half of the cost of manufacturing insulin. Therefore, purifying techniques need to be time and cost-effective while producing a sizable enough amount of product that is fit for human consumption. This method reduces volume by employing site-specific breakdown chromatography of insulin utilising the proinsulin method50. This method purifies ZZ-R proinsulin utilising an IgG-Sepharose column and IgG affinity chromatography. Before being used, the acetic acid-based supernatant, which has a pH of 8, is centrifuged for 20 minutes.

When 50ml of the solution is provided at a flow rate of 3ml/min, about 2.5g of ZZ-R proinsulin will be transmitted down the HR16/10 diameter column, which contains 12ml of IgG-Sepharose. The solution is added six times, with the last three loads using 10 mM sodium acetate at pH 8.5.A consistent 12% gel is utilised to visualise the findings of affinity chromatography using SDS-PAGE. With a Superdex 75 PC3, size exclusion chromatography is performed.This technique uses a 2/10 column with 200 mM sodium phosphate buffer supplied at a flow rate of 100 ml/min. ZZ-R proinsulin is resistant to protease degradation when it is analysed using affinity chromatography.[51]

It is then further purified using size exclusion chromatography, which has a 70% recovery rate.While additional ZZ-R proinsulin.[52] is present in trace levels, monomers make up the majority of the proinsulin that has been recovered.

10) SITE-SPECIFIC CLEAVAGE

After IgG chromatography, ultra-filtration is applied to the refined ZZ-R proinsulin, which leads to a five-fold volume reduction and an increase in concentration to 12 ml/min. Once proinsulin has been ultra-filtered, trypsin and carboxypeptidase B are utilised to break it into the C-peptide and insulin. Trypsin is employed in the digestive system to break down proteins, while carboxypeptidase is used to precisely cleave proinsulin to produce natural insulin and the C-peptide. Approximately a mass ratio of 1:1000 is utilised for ZZ-R proinsulin and trypsin, while twice as much is needed for carboxypeptidase B.Trifluoroacetic acid, carboxylic acid, and a standard pH 3 buffer are added to halt the enzymatic reaction after 30 minutes. Twenty percent acetonitrile is also added.[53]

The mixture is stored at 4°C until reverse-phase chromatography is used to further purify it.

11) REVERSE-PHASE HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY

High-performance liquid chromatography with reverse phase (RP-HPLC) is used to separate the human insulin and C-peptide. RP-HPLC is a widely used method for the analysis of insulin products because it isolates insulin into its many species and uses high pressure to expedite the procedure and increase product purity. In RP-HPLC, there are two phases used: a polar mobile phase and a non-polar stationary phase. A buffer solution containing methanol or acetonitrile can be used in the mobile phase to analyse insulin, which is large and non-polar and adheres to the stationary phase column. A wavelength range of 190–220 nanometers is used to detect insulin.

One utilises formic acid for the B chain and trifluoroacetic acid for the A chain. However, the best technique for separating the C-peptide is gel chromatography with a buffe of 1 M acetic acid.[54]

12) POLISHING WITH ZINC COMPLEXATION AND SALINE DILUTION

The goals of insulin administration are to extend the peak hours and shorten the insulin's activation time. The normal version of insulin, known as R-insulin, has an activation time of 30 to 60 minutes and peaks 2 to 4 hours post delivery. This suggests that between four and six injections must be given each day. Insulin can be made to work longer by maintaining it steady in the bloodstream, preventing the liver from removing it, and preventing cells from utilising it right away.[54] Eli Lilly & Co. has created a method that only requires two insulin injections daily for people who lead active lives. They produced 2Zn insulin, which are crystal complexes of insulin, by using zinc ions. They produced crystal compounds of insulin that are called 2Zn insulin by using zinc ions. These complexes slow down the body's generation of insulin and prevent cells from utilising it immediately because of their hexagonal shape and axial symmetry.[55] Cobalt can also be used for this. Insulin molecules collect and crystallise into suspended forms due to the weak ionic interactions between insulin and these metallic ions. Crystals are made by batch crystallisation, and their solution is maintained at 4°C. A crystal is better and more constant the longer it is active in the circulatory system.[56]

ALTERNATE METHOD

The second industrial method of making insulin is called the two-chain technique, which creates the hormone's A and B chains separately before joining them. Here, the two polypeptides are fermented with bacteria in two different fermenters and then purified. The pure A and B chains are oxidised in a cultivation, environment to form the disulfide

connections seen in human insulin. (37) Fig-3 Represents the alternate method of production of Human Insulin along with steps



Fig 3- Alternate method of Production of Human Insulin

1) GENE ISOLATION

Chains A and B of human insulin mRNA34 are encoded by complementary DNA, or cDNA, molecules made during reverse transcription. The two chains' cDNAs are amplified via PCR.

2) INSERTIONS INTO PLASMID

Both the A and B chains' DNA sequences are introduced separately into two plasmids by cutting them using restrictions enzymes. The plasmid's termination signal is found at the 3'end of the restriction sites60, and translation is initiated by ATG initiation codons on each chain's 5' terminal. In the restriction sites of plasmids EcoR1 and BamH1, there is a single chain gene. The plasmid additionally contains the lacZ gene, which aids colony screening and codes for β-galactosidase. There are additional DNA ligases added in order to connect the inserted chain gene to the plasmid.

3) TRANSFORMATIONS

The method via which recombinant plasmids infiltrate bacterial cells is called transformation. There are several ways to change E. Coli, such as electroporation and CaCl2 treatment. The cells change once the plasmid is introduced.

4) MEDIUM PREPARATIONS

LB broth is the culture medium that is used for E. Coli. After dissolving it and autoclaving it to sterilise it, lactose and ampicillin are added. Inoculant E. Coli cells that have undergone transformation are introduced to the medium.[57] Fermentation takes place in STR bioreactors using the two strains of E. coli that encode the insulin chains. In addition to sterilising the bioreactors, the pH, pO2 probe, condensers, and air inlet are calibrated.

5) BIOREACTOR FERMENTATION

A limited number of shake flasks are used to ferment recombinant E. Coli cells encoding the A and B chains in the enriched medium prior to their larger-scale use63. Due to their ability to encode β-galactosidase and show resistance to ampicillin present in the growth media, the lacZ and ampicillin resistance genes present on the plasmids are used to detect successfully converted cells. Once the transformation is complete, the cells are maintained under optimal conditions for further replication and then transferred to an industrial bioreactor. As the respective strains of E. coli multiply in various fermenters, the A and B chains are synthesised respectively.[58]

6) CRUDE PRODUCT ISOLATION

Following their removal from the bioreactor tank, the bacterial cells must be lysed by one of several methods, such as sonication, enzyme digestion, or cell freezing and thawing. Since lysosome enzymes break down bacteria's outer coat and release insulin into the surrounding medium, they are advised for usage in large-scale operations. The media may then be cleaned up by introducing detergents to remove the cell wall.[59]

7) PURIFICATION

The two required insulin chains are separated from the cell's constituent parts. Ion-exchange chromatography and gel filtering are methods used to remove impurities.

8) INSULIN CHAIN ISOLATION

Because the purified protein was bound to the plasmid gene and translated with it, it has an insulin chain that has been joined to β-galactosidase. To separate the insulin chains from the enzyme, cyanogen bromide is used because it splits the protein at the methionine residue that initiates the β-galactosidase protein.

9) CHAIN JOINING

Sodium dithionite and sodium sulfite are utilised to form the disulfide bonds that join the insulin chains (A and B). A mechanism known as reduction-reoxidation is triggered by β-mercaptoethanol and air oxidation to create human insulin.

10) REVERSE PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY

RP-HPLC is the last stage in getting rid of any impurities or reagents. After human insulin has been purified and activated, the industry can package and sell it.

SCALABILITY AND ACCESSIBILITY

Scalability is one of the main benefits of rDNA technology. This strategy, in contrast to conventional ones, enables the large-scale manufacture of insulin, satisfying the constantly expanding global need. Consequently, patients around the world now have easier access to insulin, allaying worries about shortages and price changes.

Increased Accessibility

Globally, patients now have easier access to insulin thanks to rDNA technology. The increasing need for insulin globally has been partially satisfied by rDNA technology, which has made it possible to produce insulin in vast quantities via biotechnological means. Patients in areas where access to insulin was previously restricted now have easier access to insulin thanks to this enhanced production capability.

Reduction in Production Costs

The huge reduction in insulin production costs is one of the most important accomplishments of rDNA technology. Conventional techniques for producing insulin, such removing it from animal pancreases, required a lot of work and cost money. rDNA technology, on the other hand, makes it possible to produce insulin in large quantities from genetically modified bacteria or yeast, which are less expensive to grow and maintain. Because of this, generating insulin is now less expensive, which benefits people who depend on this life-saving drug.

Addressing Insulin Shortages and Improving Supply Chain Efficiency

In order to alleviate insulin shortages and boost the effectiveness of the insulin supply chain, rDNA technology has shown to be extremely important. rDNA technology has contributed to a consistent and dependable supply of insulin for patients worldwide by raising manufacturing capacity and lowering production costs. Furthermore, having many locations for the production of insulin has decreased reliance on imports and decreased the possibility of supply chain disruptions brought on by things like trade prohibitions or delays in transit.

QUALITY CONTROL MEASURES

Strict quality control procedures guarantee that the insulin made using rDNA technology satisfies the highest requirements for effectiveness and purity. Strict testing procedures and cutting-edge analytical methods are used to ensure the finished product's efficacy and safety, giving patients and healthcare professional's alike confidence.[60]

FUTURE PROSPECTS AND INNOVATIONS

Future advancements in insulin production appear possible given the way rDNA technology is continuing to develop. Fig- 4 Represents the areas of ongoing research. These initiatives seek to increase productivity, lower production costs, and eventually increase the accessibility of insulin for individuals who require it.



Fig. 4: Areas of ongoing research for Human Insulin.

CONCLUSION

In summary, the use of recombinant DNA (rDNA) technology to produce insulin is a significant advancement in medical science that marks the beginning of a revolutionary period in the treatment of diabetes. In addition to overcoming earlier obstacles, the transition from using animal pancreases to genetically modified microbes has greatly increased the effectiveness, scalability, and accessibility of insulin.These microbial hosts have been transformed into tiny insulin factories by the clever synthesis method utilising yeast and E. coli, guaranteeing a more dependable and

durable supply chain.By addressing prior issues with animal-derived insulin shortages and contaminants, this ground-breaking method offers patients a reliable and pure medicinal supply.The scalability that rDNA technology provides is a ray of hope for people who are insulin-dependent everywhere. Because of the large-scale production capability, supply limitations are lessened, increasing insulin availability and lessening the financial burden on patients. Ensuring the safety and effectiveness of the finished product through rigorous quality control techniques is a key factor in the success of this technology.Future developments and research in the area point to even more noteworthy breakthroughs. Upcoming developments that could further improve productivity and lower production costs include new microbial hosts, enhanced fermentation procedures, and sophisticated purification methods.It is clear that rDNA technology has not only transformed the supply chain but also strengthened our commitment to enhancing the lives of persons with diabetes as we navigate the future of insulin production. The field of diabetic care is becoming more accessible and healthier thanks to the mutually beneficial link between science, technology, and healthcare.

REFERENCES

1. Walsh G. Therapeutic insulins and their large-scale manufacture. ApplMicrobiolBiotechnol, 2005; 67: 151–9.
2. Chance RE, Frank BH. Research, development, production, and safety of biosynthetic human insulin. Diabetes Care, 1993;16(Suppl. 3):133–42.
3. Mayer JP, Zhang F, DiMarchi RD. Insulin structure and function. Biopolymers, 2007; 88: 687–713.
4. Ruttenberg MA. Human insulin: facile synthesis by modification of porcine insulin. Science, 1972; 177: 623–6.
5. Obermeier R, Geiger R. A new semisynthesis of human insulin. Hoppe Seylers Z Physiol Chem, 1976; 357: 759–67.
6. Ladisch MR, Kohlmann KL. Recombinant human insulin. BiotechnolProg, 1992; 8: 469–78
7. Brogden RN, Heel RC. Human insulin. A review of its biological activity, pharmacokinetics and therapeutic use. Drugs, 1987; 34: 350–71.
8. Home PD, Thow JC, Tunbridge FK. Insulin treatment: a decade of change. Br Med Bull, 1989; 45: 92–110.
9. Everett J, Kerr D. Changing from porcine to human insulin. Drugs, 1994; 47: 286–96.
10. IDF (2012) International Diabetes Federation Clinical Guidelines Task Force: Global Guideline for Type 2 Diabetes 2012. Available at: http://www.idf.org/sites/default/files/IDF-Guideline-for-Type-2-Diabetes.pdf (accessed 9 July 2015).
11. Inzucchi SE, Bergenstal RM, Buse JB. et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care, 2012; 35: 1364–79. [PMC free article]
12. Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes, 2008; 32: S1–S201.
13. Walsh G. Therapeutic insulins and their large-scale manufacture. *Appl MicrobiolBiotechnol*, 2005; 67: 151–9.
14. Mayer JP, Zhang F, DiMarchi RD. Insulin structure and function. *Biopolymers*, 2007; 88: 687–713.
15. Chance RE, Frank BH. Research, development, production, and safety of biosynthetic human insulin. *Diabetes Care*, 1993; 16(Suppl. 3): 133–42.
16. Ladisch MR, Kohlmann KL. Recombinant human insulin. *Biotechnol Prog*,1992; 8: 469–78.
17. Sandow J, Landgraf W, Becker R, Seipke G. Equivalent recombinant human insulin preparations and their place in therapy. Eur Endocrinology, 2015; 11: 10–6.

18. DeLawter DE, Moss JM. Human insulin: a double-blind clinical study of its effectiveness. South Med J., 1985; 78: 633–5.
19. Drugs@FDA: FDA Approved Drug Products: Search Insulin. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchType=BasicSearch&searchTerm=insulin (accessed 7 September 2015).
20. Mann NP, Johnston DI, Reeves WG, Murphy MA. Human insulin and porcine insulin in the treatment of diabetic children: comparison of metabolic control and insulin antibody production. Br Med J., 1983; 287: 1580–2.
21. Jovanovic-Peterson L, Kitzmiller JL, Peterson CM. Randomized trial of human versus animal species insulin in diabetic pregnant women: improved glycemic control, not fewer antibodies to insulin, influences birth weight. Am J Obstet Gynecol, 1992; 167: 1325–30
22. Markussen J, Damgaard U, Pingel M. et al. Human insulin (Novo): chemistry and characteristics. Diabetes Care, 1983; 6(Suppl. 1): 4–8.
23. Pedersen C, Hoegholm A. A comparison of semisynthetic human NPH insulin and porcine NPH insulin in the treatment of insulin-dependent diabetes mellitus. Diabet Med, 1987; 4: 304–6.
24. Deckert T. The immunogenicity of new insulins. Diabetes, 1985; 34(Suppl. 2): 94–6.
25. Van Haeften TW. Clinical significance of insulin antibodies in insulin-treated diabetic patients. Diabetes Care, 1989; 12: 641–8.
26. Lauritano AA, Clements RS Jr, Bell D. Insulin antibodies in non-insulin-dependent diabetes mellitus: effect of treatment with semisynthetic human insulin. Clin Ther, 1989; 11: 268–77.
27. Schernthaner G. Immunogenicity and allergenic potential of animal and human insulins. Diabetes Care, 1993; 16(Suppl. 3): 155–65.
28. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care, 2003 ;26: 1902–12.
29. Cryer PE. Hypoglycemia in type 1 diabetes mellitus. EndocrinolMetabClin North Am, 2010; 39: 641–54.
30. Seaquist ER, Anderson J, Childs B. et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care, 2013; 36: 1384–95.
31. Owens DR. Stepwise intensification of insulin therapy in type 2 diabetes management-exploring the concept of the basal-plus approach in clinical practice. Diabetic Med, 2013; 30: 276–88.
32. Fletcher JA, Barnett AH, Pyke DA. et al. Transfer from animal insulins to semisynthetic human insulin: a study in four centres. Diabetes Res, 1990; 14: 151–8.
33. Davidson JA, Ramirez LC, Raskin P, Selam JL. Transfer of patients with diabetes from semisynthetic human insulin to human insulin prepared by recombinant DNA technology using baker's yeast: a double-blind, randomized study. Clin Ther, 1991; 13: 557–68.
34. Raskin P, Clements RS Jr. The use of human insulin derived from baker's yeast by recombinant DNA technology. Clin Ther, 1991; 13: 569–78.
35. Aronoff S, Goldberg R, Kumar D. et al. Use of a premixed insulin regimen (Novolin 70/30) to replace self-mixed insulin regimens. Clin Ther, 1994; 16: 41–49.
36. Beyer J, Enzmann F, Lauerbach M. et al. Treatment with human insulin (recombinant DNA) in diabetic subjects pretreated with pork or beef insulin: first results of a multicenter study. Diabetes Care, 1982; 5(Suppl. 2): 140–148.
37. Galloway JA, Root MA, Bergstrom R. et al. Clinical pharmacologic studies with human insulin (recombinant DNA) Diabetes Care, 1982; 5(Suppl. 2): 13–22.

38. Garber AJ, Davidson JA, Krosnick A. et al. Impact of transfer from animal-source insulins to biosynthetic human insulin (rDNA E coli) in patients with diabetes mellitus. Clin Ther, 1991; 13: 627–636.
39. Bell DS, Cutter GR, Lauritano AA. Efficacy of a premixed semisynthetic human insulin regimen. Clin Ther, 1989; 11: 795–801.
40. Brodows R, Chessor R. A comparison of premixed insulin preparations in elderly patients. Efficacy of 70/30 and 50/50 human insulin mixtures. Diabetes Care, 1995; 18: 855–857.
41. WC500033779 Insuman scientific discussion, updated 2005. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000201/WC500033779.pdf] (access 9 July 2015).
42. Gualandi-Signorini AM, Giorgi G. Insulin formulations – a review. Eur Rev Med Pharmacol Sci, 2001; 5: 73–83.
43. Study 1006 (1995). Comparison of the pharmacodynamics and pharmacokinetics of HOE31 HGT (biosynthetic human insulin) and HOE31 H (semi-synthetic human insulin) using the euglycaemic clamp technique. Clinical Study report A1 HOE 31 HGT/2/D/111
44. Study 302 (1995). Comparison of the efficacy and safety of different biosynthetic and semisynthetic human insulin formulations in a 24-week therapeutic trial. Clinical Study report B1 HOE 36 HGT/2/MN/302/DM
45. Study 3002 (2000). Comparison of safety and efficacy of recombinant human insulin of Hoechst Marion Roussel and of Eli Lillly in type 2 Diabetic patients requiring insulin treatment (HR1799A/3002). Clinical study report No. F2000CLN0624; 2000,
46. Kalra S, Balhara YS, Baruah MP. et al. The first Indian recommendations for best practices in insulin injection technique. Indian J EndocrMetab, 2012; 16: 876–885.
47. Study HR1799A-1001 (1997). Comparisons of the pharmacodynamics and pharmacokinetics of biosynthetic regular human insulin (Hoechst Marion Roussel) and biosynthetic regular human insulin (Eli Lilly) by using the euglycemic clamp technique. Clinical study report
48. Study HR1799A-1003 (1997). Comparisons of the pharmacodynamics and pharmacokinetics of biosynthetic basal human insulin (Hoechst Marion Roussel) and biosynthetic basal human insulin (Eli Lilly) by using the euglycemic clamp technique. Clinical study report
49. Jeandidier N, Selam JL, Renard E. et al. Decreased severe hypoglycemia frequency during intraperitoneal insulin infusion using programmable implantable pumps. Evadiac Study Group. Diabetes Care. 1996;19:780
50. Selam JL. External and implantable insulin pumps: current place in the treatment of diabetes. Exp Clin Endocrinol Diabetes, 2001; 109(Suppl. 2:): S333–40.
51. Duckworth W, Davis SN. Comparison of insulin glargine and NPH insulin in the treatment of type 2 diabetes: a review of clinical studies. J Diab Complications, 2007; 21: 196–204.
52. Yki-Jarvinen H, Ryysy L, Nikkila K. et al. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med, 1999; 130: 389–396.
53. Hermanns N, Kulzer B, Kohlmann T. et al. Treatment satisfaction and quality-of-life between type 2 diabetes patients initiating long- vs. intermediate-acting basal insulin therapy in combination with oral hypoglycemic agents – a randomized, prospective, crossover, open clinical trial. Health and Quality of Life Outcomes, 2015; 13: 77–90.
54. Cusi K, Cunningham GR, Comstock JP. Safety and efficacy of normalizing fasting glucose with bedtime NPH insulin alone in NIDDM. Diabetes Care, 1995; 18: 843–851. [PubMed] [Google Scholar]

55. Rosenstock J, Schwartz SL, Clark CM Jr. et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care, 2001; 24: 631–633
56. Massi Benedetti M, Humburg E, Dressler A, Ziemen M. A one- year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. HormMetab Res, 2003; 35: 189–96.
57. Tschiedel B, Almeida O, Redfearn J, Flacke F. Initial experience and evaluation of reusable insulin pen devices among patients with diabetes in emerging countries. Diabetes Therapy, 2014; 5: 545–55.
58. Kitzmiller JL, Block JM, Brown FM. et al. Managing preexisting diabetes for pregnancy: summary of evidence and consensus recommendations for care. Diabetes Care, 2008; 31: 1060–79. [PMC free article]
59. Agarwal MM, Punnose J. Recent advances in the treatment of gestational diabetes. Expert OpinInvestig Drugs, 2004; 13: 1103–11.
60. Barnett A, Begg A, Dyson P. et al. Insulin for type 2 diabetes: choosing a second-line insulin regimen. Int J ClinPract, 2008; 62: 1647–53.